Obesity and COPD: pathophysiological aspects and therapeutic perspectives
https://doi.org/10.24884/1609-2201-2024-103-4-11-19
Abstract
This article describes the relationship between the pathogenetic mechanisms of obesity and chronic obstructive pulmonary disease. Particular attention is paid to the role of systemic inflammation, metabolic disorders and mechanical influence of excess adipose tissue on the external respiratory function. Understanding the peculiarities of multifactorial pathophysiologic interaction in patients with such combined pathology allows to set the accents in the complex approach in treatment. Rational approach, taking into account both pharmacotherapy and non-medication methods when choosing treatment tactics, positively affects clinical outcomes. The authors suggest that targeting and influencing the common therapeutic targets of both diseases should be considered as a priority. The data of the analysis can serve as a basis for the development of new algorithms for the treatment of patients with obesity and COPD, as well as for the improvement of existing clinical guidelines.
About the Authors
D. V. Ladnov
Pavlov University
Russian Federation
Russian Federation
Dmitry V. Ladnov - general practitioner, assistant of the Department of General Medical Practice (Family Medicine).
6‒8, L’va Tolstogo str., St. Petersburg, 197022
N. L. Shaporova
Pavlov University
Russian Federation
Russian Federation
Natalia L. Shaporova - Dr. of Sci. (Med.), Professor, Head of the Department of General Medical Practice (Family Medicine).
St. Petersburg
Yu. Sh. Khalimov
Pavlov University
Russian Federation
Russian Federation
Yuriy Sh. Khalimov - Dr. of Sci. (Med.), Professor, Honored Physician of the Russian Federation, Chief Endocrinologist of the Health Care Committee of the Government of St. Petersburg, Chief Endocrinologist of the Ministry of Defense of the Russian Federation, Head of the Department of Faculty Therapy with a Course of Endocrinology, Cardiology with a Clinic named after Acad. G. F. Lang.
St. Petersburg
References
1. Seidell J. C. Worldwide and Regional Prevalence of Obesity. Handbook of Obesity, Volume 1: Epidemiology, Etiology, and Physiopathology. 4th ed. Bray G. A., Bouchard C. (eds.). Vol. 1. CRC Press. 2024. P. 48–52. https://doi.org/10.1201/9781003437673-6.
2. Ward Z. J., Bleich S. N., Cradock A. L. et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440–2450. https://doi.org/10.1056/NEJMsa1909301.
3. Yusenko S. R., Zubkova T. S., Sorokin A. S., Khaltourina D. A. Obesity in Russia: prevalence dynamics and sex and age structure since the end of the 20th century. Public Health. 2024;4(3):17–29. (In Russ.). https://doi.org/10.21045/2782-1676-2024-4-3-17-29.
4. Dhurandhar E. J., Keith S. W. The aetiology of obesity beyond eating more and exercising less. Best Pract Res Clin Gastroenterol. 2014;28(4):533–544. https://doi.org/10.1016/j.BPG.2014.07.001.
5. Kadouh H. C., Acosta A. Current paradigms in the etiology of obesity. Techniques in Gastrointestinal Endoscopy. 2017;19(1):2–11. https://doi.org/10.1016/j.tgie.2016.12.001.
6. Vanfleteren L. E., Spruit M. A., Groenen M. et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728– 735. https://doi.org/10.1164/rccm.201209-1665OC.
7. Zewari S., Hadi L., van den Elshout F. et al. Obesity in COPD: Comorbidities with Practical Consequences? COPD: J Chron Obstruct Pulmon Dis. 2018;15(5):464–471. https://doi.org/10.1080/15412555.2018.1509951.
8. García-Rio F., Soriano J. B., Miravitlles M. et al. Impact of obesity on the clinical profile of a population-based sample with chronic obstructive pulmonary disease. PLOS ONE. 2014;9(8):e105220. https://doi.org/10.1371/journal.pone.0105220.
9. Koniski M., Salhi H., Lahlou A. et al. Distribution of body mass index among subjects with COPD in the Middle East and North Africa region: data from the BREATHE study. Int J Chron Obstruct Pulmon Dis. 2015;10(1):1685–1694. https://doi.org/10.2147/COPD.S87259.
10. Lambert A. A., Putcha N., Drummond M. B. et al. Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. Chest. 2017;151(1):68–77. https://doi.org/10.1016/j.chest.2016.08.1432.
11. Dixon A. E., Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755–767. https://doi.org/10.1080/17476348.2018.1506331.
12. Considine R. V., Sinha M. K., Heiman M. L. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–295. https://doi.org/10.1056/NEJM199602013340503.
13. Ferrante A. W. Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med. 2007;262(4):408–414. https://doi.org/10.1111/j.1365-2796.(2007).01852.x.
14. Palma G., Sorice G. P., Genchi V. A. et al. Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity. Int J Mol Sci. 2022;23(13):7349. https://doi.org/10.3390/ijms23137349.
15. Broekhuizen R., Vernooy J. H., Schols A. M. et al. Leptin as local inflammatory marker in COPD. Respir Med. 2005;99(1):70–74. https://doi.org/10.1016/j.rmed.2004.03.029.
16. Küpeli E., Ulubay G., Ulasli S. S. et al. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine. 2010;38(1):76–82. https://doi.org/10.1007/s12020-010-9351-3.
17. Mineev V. N., Lalaeva T. M., Trofimov V. I. Bronchial asthma and obesity: common mechanisms. Clinical Medicine. 2012;90(4):4–10. (In Russ.). URL: https://cyberleninka.ru/article/n/bronhialnaya-astma-i-ozhirenie-obschie-mehanizmy (accessed: 20.12.24.)
18. Agustí A., Edwards L. D., Rennard S. I. et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. https://doi.org/10.1371/journal.pone.0037483.
19. Omarjee B., Budhan S. Symptom profile in obese COPD (Chronic Obstructive Pulmonary Disease) patients compared with non-obese patients: retrospective evaluation in the French overseas department of Reunion Island (period 2015-2020). Eur Respir J. 2022;60(66):1358. https://doi.org/10.1183/13993003.congress-2022.1358.
20. Endalifer M. L., Diress G. Epidemiology, Predisposing Factors, Biomarkers, and Prevention Mechanism of Obesity: A Systematic Review. J Obes. 2020;2020:6134362. https://doi.org/10.1155/2020/6134362.
21. Brandão I., Martins M. J., Monteiro R. Metabolically Healthy Obesity-Heterogeneity in Definitions and Unconventional Factors. Metabolites. 2020;10(2):48. https://doi.org/10.3390/metabo10020048.
22. Druzhilov М. A., Kuznetsova Т. Yu. Heterogeneity of obesity phenotypes in relation to cardiovascular risk. Cardiovascular Therapy and Prevention. 2019;18(1):161–167. (In Russ.). https://doi.org/10.15829/1728-8800-2019-1-161-167.
23. Binvignat M., Sellam J., Berenbaum F. et al. The role of obesity and adipose tissue dysfunction in osteoarthritis pain. Nat Rev Rheumatol. 2024;20:565–584. https://doi.org/10.1038/s41584-024-01143-3.
24. Guo Y., Zhang T., Wang Zh. et al. Body mass index and mortality in chronic obstructive pulmonary disease: A dose– response meta-analysis. Medicine. 2016;95(28):e4225. https://doi.org/10.1097/md.0000000000004225.
25. Schols A. M., Slangen J., Volovics L., Wouters E. F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1791–1797. https://doi.org/10.1164/ajrccm.157.6.9705017.
26. Marquis K., Debigaré R., Lacasse Y. et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(6):809–813. https://doi.org/10.1164/rccm.2107031.
27. Galesanu R. G., Bernard S., Marquis K. et al. Obesity in chronic obstructive pulmonary disease: is fatter really better? Can Respir J. 2014;21(5):297–301. https://doi.org/10.1155/2014/181074.
28. Simoes D. C. M., Vogiatzis I. Can muscle protein metabolism be specifically targeted by exercise training in COPD? J Thorac Dis. 2018;10(Suppl 12):S1367–S1376. https://doi.org/10.21037/jtd.2018.02.67.
29. Park H. Y., Kim T., Kim H. et al. Increase in physical activity reduces chronic obstructive pulmonary disease mortality: an emulated target trial using nationwide cohort data. Chest. 2023;164(4):A5050–A5050. https://doi.org/10.1016/j.chest.2023.07.3272.
30. Goto T., Hirayama A., Faridi M. K. et al. Obesity and Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2018;15(2):184–191. https://doi.org/10.1513/AnnalsATS.201706-485OC.
31. Jordan J. G. Jr., Mann J. R. Obesity and mortality in persons with obstructive lung disease using data from the NHANES III. South Med J. 2010;103(4):323–330. https://doi.org/10.1097/sMJ.0b013e3181d394b4.
32. Obesity: clinical guidelines, 2020. Ministry of Health of the Russian Federation [official website] (In Russ.). URL: https://cr.minzdrav.gov.ru/recomend/28_2 (accessed: 20.12.24).
33. Benbaibeche H., Saidi H., Bounihi A., Koceir E. A. Emotional and external eating styles associated with obesity. J Eat Disord. 2023;11(1):67. https://doi.org/10.1186/s40337-023-00797-w.
34. Gal A. M., Dumitrascu O., Gherasim A. et al. Validation and Comparison of DEBQ and TEMS in Assessing Eating Behaviours in the Romanian Adult Population. Proceedings. 2023;91(1):152. https://doi.org/10.3390/proceedings2023091152.
35. Zhou W., Zhang J., Yan M. et al. Orlistat induces ferroptosislike cell death of lung cancer cells. Front Med. 2021;15(6):922– 932. https://doi.org/10.1007/s11684-020-0804-7.
36. Guven A., Koksal N., Cetinkaya A. et al. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab. 2004;6(1):50–55. https://doi.org/10.1111/j.1463-1326.2004.00314.x.
37. Foer D., Strasser Z. H., Cui J. et al. Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes. Am J Respir Crit Care Med. 2023;208(10):1088–1100. https://doi.org/10.1164/rccm.202303-0491OC.
38. Altintas Dogan A. D., Hilberg O., Hess S. et al. Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2022;17:405–414. https://doi.org/10.2147/COPD.S350133.
39. Xie Z., Yang S., Deng W. et al. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clinical Epidemiology. 2022;14:1463–1476. https://doi.org/10.2147/CLEP.S391819.
40. Chronic obstructive pulmonary disease: clinical guidelines, 2021. Ministry of Health of the Russian Federation [official website]. (In Russ.). URL: https://cr.minzdrav.gov.ru/recomend/603_2 (accessed: 20.12.24).
41. Wangberg H., Mortazavi D., Kitsen J. et al. Dose-dependent association between inhaled corticosteroid use and risk of obesity and metabolic syndrome in asthma. Allergy Asthma Proc. 2022;43(5):446–453. https://doi.org/10.2500/aap.2022.43.220027.
42. Global Initiative for Chronic Obstructive Lung Disease. 2024. URL: https://goldcopd.org/2024-gold-report/ (accessed: 20.12.24).
43. Xu W., Zhang J., Xiao J. Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway. Front Endocrinol (Lausanne). 2021;12:662451–662451. https://doi.org/10.3389/FENDO.2021.662451.
44. Möllmann J., Kahles F., Lebherz C. et al. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. Diabetes Obes Metab. 2017;19(4):496–508. https://doi.org/10.1111/dom.12839.
45. Gyldenløve M., Sørensen J. A., Fage S. et al. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis – results from a randomized controlled trial (PSORRO). J Am Acad Dermatol. 2024;91(1):64–71. https://doi.org/10.1016/j.jaad.2024.02.036.
Review
For citations:
Ladnov D.V., Shaporova N.L., Khalimov Yu.Sh. Obesity and COPD: pathophysiological aspects and therapeutic perspectives. New St. Petersburg Medical Records. 2024;(4):11-19. (In Russ.) https://doi.org/10.24884/1609-2201-2024-103-4-11-19
Views:
80
Email this article 